Latest News

The most successful investors know when to break the usual rules. This could be one of those times.

The AI giant is growing fast, but there’s still a lot investors don’t know.

Learn how to calculate your emergency fund in five minutes, set a realistic savings target and keep emergency cash separate from investments.

The 2028 COLA could be even larger for one key reason.

Berkshire sees the ailing U.S. housing industry as a long-term opportunity.

Valero posted record Q3 revenue and EPS on soaring refining margins, but shares sold off on light Q4 guidance and concerns over Russian diesel imports and crude price pressure.

RSPH offers broader healthcare exposure with lower volatility and higher dividend yield, while IBB provides concentrated biotech focus with stronger recent returns.

Adobe trades at a 7.2x forward P/E discount to DocuSign, while DocuSign is pivoting beyond e-signatures to agreement management.

Dogecoin has a bold new strategy to outgrow its meme coin origins. But will it actually work?

Engagement trends have been a primary overhang on the stock.

Acumen Pharmaceuticals (NASDAQ:ABOS) said it expects to report top-line results in November from its Phase II ALTITUDE-AD trial of sabirnetug, an investigational antibody designed to target soluble amyloid-beta oligomers in patients with Alzheimer’s disease. Chief Executive Officer Dan O’Connell sa

Canadians have ways to supplement government pensions and may not need a multi-million-dollar nest egg to retire comfortably.

Lockheed Martin, Interactive Brokers and American Electric Power raised dividends, with payout ratios near or below 60% pointing to sustainable future increases.

Amid a Russell 2000 sell-off driven by rising rates, FIBK, EPAC, CCS, and HRMY show varied resilience, with analysts weighing risks against potential upside in each stock.

AI revenue surged 29% sequentially as macro headwinds tempered overall growth.

Asset management AUM grew to $61 billion with strong mortgage servicing performance.

International expansion lifts revenue 18.9% amid traffic headwinds and margin compression.

Spending worries ran through all three sell-offs. Has the stock slid far enough?

Robinhood has done an impressive job of building its business, but investors are pricing in high expectations even after a big drawdown.

Loblaw's small dividend offers room for growth, while its share price requires more than a quieter inflation report.

Moderna stock yo-yoed Monday on more muted expectations for its Merck-partnered cancer vaccine, INT.

Dutch Bros is growing revenue at higher rates, while Lululemon trades at a lower earnings multiple.

Micron's fourth quarter earnings were nothing short of spectacular, but the stock is getting punished anyway.

CrowdStrike trades at a premium valuation despite recent losses, while Axon commands a lower multiple with profitable growth, a stark contrast that reshapes the risk-reward calculus.

Chord Energy shares have surged over 70% in 2026 on higher oil prices and strong free cash flow, fueling dividends and buybacks ahead of its Nov. 4 earnings report.